As of Beijing time The data is from a third-party organization and is only for reference.
For actual information, please refer to:www.eastmoney.com
Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)
Tel: +1(626)986-9880
Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK
Tel: 0044 7790 816 954
Email: marketing@medicilon.com
Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)
Postcode: 201299
Tel: +86 (21) 5859-1500 (main line)
Fax: +86 (21) 5859-6369
© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888 | Website Map
Business Inquiry
Global:
Email:marketing@medicilon.com
+1(626)986-9880(U.S.)
0044 7790 816 954 (Europe)
China:
Email: marketing@medicilon.com.cn
Tel: +86 (21) 5859-1500
Recently, the FDA launched the Medical Device Biocompatibility Evaluation Resource Center, an online system designed to help users better understand and complete the biocompatibility evaluation of medical devices. This system is not intended to replace the international standard ISO 10993-1 “Biological evaluation of medical devices-Part 1: Evaluation and testing within a risk management process,”, but is based on the standard and the official guide FDA’s Biocompatibility Guidance on Use of ISO 10993- 1. On-line a visualized online guidance system.
The FDA recommends that users read the official guidelines for biocompatibility assessment, ISO 10993-1, guidelines for specific devices, and class II device classification control documents, and then follow the steps below to complete the biocompatibility assessment:
When is biocompatibility information needed? FDA conducts biocompatibility evaluation or evaluation of products. How does FDA conduct biocompatibility evaluation of products or evaluate biocompatibility points that FDA is concerned about? Biocompatibility glossary
Endpoints are established according to device classification: surface contact devices, external substance exchange devices, and implanted devices. End points are established according to the continuous contact time: limited contact (within 24h), long-term contact (24h~30d), permanent contact (greater than 30d)
Record and analyze the declared devices and biocompatibility test literature for comparison, and also need to compare with the devices already on the market.
Comparative analysis of components, components and ingredients Comparative analysis of the entire device
The evaluation test report should contain the following content:
The contents of all test reports are prepared to be used for comparison. The test literature test parameters and acceptance criteria results analysis conclusions